Supplier Quality Intern
About the job
- Candidate for an undergraduate degree in sciences or engineering.
- Able to navigate Windows-based software.
- Familiar with Microsoft Word styles functionality for developing templates.
- Able to update SmartSheet.
- Able to communicate effectively with colleagues at all levels using clear and concise language.
- Work with stakeholders to establish a reduced number of templates for respective supplier types.
- Collaborate with supplier quality, supply chain, legal, and other impacted areas to gain buy-in and put the Supplier Quality Agreement templates in control.
- Develop a work instruction for each Supplier Quality Agreement template type.
- Develop a schedule for Supplier Quality Agreement periodic reviews and a process for updating agreements with suppliers and stakeholders as needed.
- Support the Supplier Quality team with developing new Supplier Quality Agreement templates, defining a sustainable process, identifying stakeholders, and executing the work.
About the company
Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Melbourne, Australia
Founded
2015
Get referred to Telix Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approved Pixclara on September 13, 2026, opening Telix's first brain-cancer imaging market.
- H1 2026 revenue reached $477 million, up 22%, with EBITDA rising 146%.
- BiPASS enrolled 350 patients and Telix aligned with FDA on a U.S. NDA pathway.
What critics are saying
- Telix still depends on FDA manufacturing acceptance for Zircaix resubmission in 2026.
- The $2.35 billion ITM deal brings dilution, debt, and integration strain through 2027.
- Novartis, with Lutathera and Pluvicto, attacks Telix in GEP-NETs and prostate therapy.
What makes Telix Pharmaceuticals unique
- Telix sells both diagnostics and therapies across the same radiopharmaceutical platform.
- Illuccix and Gozellix give Telix a commercial prostate imaging franchise in 24 countries.
- ITM adds isotope manufacturing, distribution, and lutetium-177 supply across more than 65 countries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Annual Performance Bonus
- Equity-Based Incentive Program
- Paid Vacation
- Paid Wellness Days
- Hybrid Work Options
- Remote Work Options